Latha M S, Martis Jacintha, Shobha V, Sham Shinde Rutuja, Bangera Sudhakar, Krishnankutty Binny, Bellary Shantala, Varughese Sunoj, Rao Prabhakar, Naveen Kumar B R
Global Medical Affairs, Dr. Reddy's Laboratories Ltd., Hyderabad, India;
J Clin Aesthet Dermatol. 2013 Jan;6(1):16-26.
The increasing incidence of skin cancers and photodamaging effects caused by ultraviolet radiation has increased the use of sunscreening agents, which have shown beneficial effects in reducing the symptoms and reoccurrence of these problems. Many sunscreen compounds are in use, but their safety and efficacy are still in question. Efficacy is measured through indices, such as sun protection factor, persistent pigment darkening protection factor, and COLIPA guidelines. The United States Food and Drug Administration and European Union have incorporated changes in their guidelines to help consumers select products based on their sun protection factor and protection against ultraviolet radiation, whereas the Indian regulatory agency has not yet issued any special guidance on sunscreening agents, as they are classified under cosmetics. In this article, the authors discuss the pharmacological actions of sunscreening agents as well as the available formulations, their benefits, possible health hazards, safety, challenges, and proper application technique. New technologies and scope for the development of sunscreening agents are also discussed as well as the role of the physician in patient education about the use of these agents.
皮肤癌发病率的上升以及紫外线辐射造成的光损伤效应,使得防晒剂的使用增多,而防晒剂已显示出在减轻这些问题的症状及复发方面具有有益效果。目前有多种防晒化合物在使用,但它们的安全性和有效性仍存在疑问。有效性通过诸如防晒系数、持续色素沉着变黑防护系数以及欧洲化妆品、个人护理品和香水协会(COLIPA)指南等指标来衡量。美国食品药品监督管理局和欧盟已在其指南中做出修订,以帮助消费者根据防晒系数和对紫外线辐射的防护来选择产品,而印度监管机构尚未就防晒剂发布任何特别指导,因为它们被归类为化妆品。在本文中,作者讨论了防晒剂的药理作用、现有配方、它们的益处、可能的健康危害、安全性、挑战以及正确的使用技术。还讨论了防晒剂开发的新技术和发展空间,以及医生在对患者进行这些产品使用教育方面所起的作用。